TNF Pharmaceuticals Salute del bilancio
Salute finanziaria criteri di controllo 5/6
TNF Pharmaceuticals has a total shareholder equity of $382.3K and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $26.4M and $26.0M respectively.
Informazioni chiave
0%
Rapporto debito/patrimonio netto
US$0
Debito
Indice di copertura degli interessi | n/a |
Contanti | US$13.07m |
Patrimonio netto | US$382.29k |
Totale passività | US$26.00m |
Totale attività | US$26.38m |
Aggiornamenti recenti sulla salute finanziaria
Recent updates
We Think MyMD Pharmaceuticals (NASDAQ:MYMD) Needs To Drive Business Growth Carefully
Sep 01We're Keeping An Eye On MyMD Pharmaceuticals' (NASDAQ:MYMD) Cash Burn Rate
May 19MyMD Pharma receives grant from European patent office for Supera-CBD compound
Aug 30Oramed, MyMD surge on plans for early-stage oral COVID vaccine data release in Q3
Jul 08Companies Like MyMD Pharmaceuticals (NASDAQ:MYMD) Could Be Quite Risky
Apr 12MyMD Pharmaceuticals (NASDAQ:MYMD) Is In A Good Position To Deliver On Growth Plans
Aug 29Analisi della posizione finanziaria
Passività a breve termine: TNFA's short term assets ($14.4M) exceed its short term liabilities ($5.8M).
Passività a lungo termine: TNFA's short term assets ($14.4M) do not cover its long term liabilities ($20.2M).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: TNFA is debt free.
Riduzione del debito: TNFA currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Bilancio
Analisi della pista di contanti
Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.
Pista di liquidità stabile: TNFA has sufficient cash runway for more than a year based on its current free cash flow.
Previsione Cash Runway: TNFA has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 10.2% each year.